News & Insights

Stay Informed With Our Latest Updates

Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Insights > Keyword
Insights > Type
Global > Practices
Global > Industries
Insights > Location
Insights > Person
Insights > Date Filter
4518 Results Found

Firm News July 15, 2026

Gibson Dunn Advised ERock on Initial Public Offering

Gibson Dunn advised ERock, Inc. on its initial public offering. ERock is a leader in reliable, large-scale onsite power solutions.

Firm News March 26, 2026

Gibson Dunn Advises Apogee Therapeutics on $402.5 Million Offering of Common Stock

Gibson Dunn represented Apogee Therapeutics, Inc. in a public offering of common stock that generated aggregate gross proceeds of approximately $402.5 million to Apogee.

Firm News February 17, 2026

Gibson Dunn Advised Galecto on Public Offering of Common Stock

Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.

Firm News December 17, 2025

Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings

Firm News November 17, 2025

Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of $575 Million

Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of $575 million to Cogent

Firm News October 28, 2025

Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters’ option to purchase additional shares for gross proceeds of $155.3 million

Firm News October 15, 2025

Gibson Dunn Advises Jade Biosciences on $135 Million Private Placement

Gibson Dunn represented Jade Biosciences, Inc. in connection with a private placement of securities generating aggregate gross proceeds of approximately …

Firm News October 10, 2025

Gibson Dunn Represented Apogee Therapeutics on $345 Million Offering of Common Stock and Pre-Funded Warrants

Gibson Dunn represented Apogee Therapeutics, Inc., a clinical-stage biotechnology company, in a public offering of 8,048,782 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,097,561 shares.